...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Primary Endpoint Results for Phase 3 BETonMACE Cardio Outcomes Trial were Announced September 30th ****Detailed Trial Data to be Presented at AHA Late Breaking Session Nov 16th & Company Webcast Nov 18th******

Free
Message: Q4 2019 Events

This is not an official company list of Q4 2019 events. Here's the October 2019 company fact sheet. Event list below was updated 10/12/2019 to include 3 ASN abstracts and the Society for Neuroscience abstract. There is so much more beyond just the BETonMACE top-line primary endpoint that we have yet to hear about. It will be an exciting time between now and mid-November AHA!

Neuroscience 2019: October 19-23; Chigago, IL. Resverlogix will present a poster. Click below for the abstract.

October 21st: Apabetalone epigenetically inhibits monocyte adhesion to brain endothelial cells by downregulating key neuroinflammation markers in vitro and in vivo

 

BIO Investor Forum: October 22-23, 2019; San Francisco, California. Resverlogix and Zenith are both on the list of presenting companies.

 

AGM Meetings: October 31st, 2019 for both Resverlogix and Zenith.

 

American Society for Nephrology (ASN) Kidney Week: Nov 5-10, 2019; Washington, D.C. Click on the links below for the abstracts. A big focus on alkaline phosphatase. There does not appear to be a BETonMACE CKD-sub-study presentation on the schedule, but a top-line statement on the CKD sub-study results could come ahead of or during ASN.

November 8th: 1048: Apabetalone Lowers Serum Alkaline Phosphatase in CVD Patients with and Without CKD and Improves Cardiovascular Risk

November 8th: 317: Association of Serum Alkaline Phosphatase with CKD and Cognitive Function in Patients with Diabetes and Acute Coronary Syndrome

November 9th: 782: Apabetalone Downregulates Alkaline Phosphatase and Improves Cardiovascular Risk

 

BIO-Europe: Nov 11-13, 2019. Both Resverlogix and Zenith are on the list of presenting companies.

 

American Heart Association (AHA): November 16-18, 2019; Philadelphia, PA. The full detailed results for the BETonMACE primary endpoint will be presented by Dr. Kausik Ray on Nov 16th. Plus, another alkaline phosphatase presentation. Abstracts currently embargoed.

November 16th, 11:42-11:50 AM. Effect of BET Protein Inhibition With Apabetalone on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes - Results of the BETonMACE Trial

November 18th, 11:30-12:00 PM. ALP Levels Predict Adverse Cardiovascular Outcomes and Cognitive Impairment in High Risk Patients

 

Clinical Trials on Alzheimer's Disease (CTAD): December 4-7, 2019; San Diego, CA. Two presentations in the final program on Thursday Dec 5th during the symposium on "Epigenetics and the BET-system in vascular dementia, Alzheimer’s disease and mixed dementia – the problem and potential remedies." One of them is the BETonMACE cognition sub-study. A top-line statement on the cognition sub-study results could come ahead of CTAD.

PRESENTER 3: The epigenetic inhibitor APABETALONE corrects pathophysiological brain endothelial and microglial cell activation that contributes to neurodegenerative disease Ewelina Kulikowski, SVP Research and Development, Resverlogix Corporation, Calgary, Canada

PRESENTER 4: Epigenetics, the BET-system, Alzheimer’s Disease and Vascular Cognitive Impairment; The BETonMACE study and effects of apabetalone 100 mg b.i.d. two years treatment on cognition in diabetes patients with established cardiovascular disease Jeffrey Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

Share
New Message
Please login to post a reply